The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

Antibodies to watch and more

by

The Antibody Society’s presentation, “Antibodies to watch and more: Early and late-stage clinical development trends” was given on June 26, 2019, as part of KNect365’s Digital Week.

In this presentation, Dr. Janice Reichert, Executive Director of the Society, provided an update to the Antibodies to Watch in 2019 paper, which was published in mAbs in February. She gave a brief summary of antibody therapeutics approved January to June this year in either the US or EU, and antibodies in regulatory review and those that might enter regulatory review soon. Dr. Reichert also discussed trends for nearly 160 antibodies that entered clinical study from January 2018 to mid-June 2019, including use of different antibody formats and mechanisms of action, and she provided specifics regarding the popular and less trendy targets.

Click here to download the presentation and learn which antibodies are the ones to watch in 2019 and 2020!

Like this post but not a member? Please join!

The Antibody Society maintains a comprehensive table of approved mAb therapeutics and those in regulatory review in the EU or US. Located in the ‘Web Resources’ section of our website, the list is updated regularly and can be downloaded in Excel format.

Antibody Engineering & Therapeutics Europe 2019

by

Thank you for joining us at The Antibody Society’s 2nd annual Antibody Engineering & Therapeutics Europe meeting (AE&TE) June 11-13 2019. The meeting was a great opportunity for Society members to connect with industry and academic scientists and executives from Europe and around the world focused on antibody and protein therapeutic discovery and development.

As always, The Antibody Society’s members designed the scientific program and acted as session Chairs. The meeting featured sessions on Turning Antibody Leads into Drugs, Recent Advances in Immuno-Oncology Approaches, Bioinformatics and Repertoires in Antibody Discovery and Development, Antibody Therapeutics for Autoimmune and Neurodegenerative Diseases, Clinical Developments in Antibody Therapeutics, and New Antibody Formats and Effector Functions.

AE&TE Student/Postdoc Poster Competition

The Society sponsored a poster competition for students and postdocs, with winners receiving complimentary registration, support for travel expenses, and an opportunity to present at the conference. Congratulations to the winners, Roberta Lotti and Amiram Sananes!

“I would really thank The Antibody Society for giving me this opportunity to grow and enlarge my research horizon.This award gave me the opportunity to get in touch with a new research community and, as I hope, to enlarge my contacts and my collaborations. ” – Roberta Lotti

“I believe it’s important for students to attend these conferences and come out from their shell once in a while, and in doing so get new ideas while enjoying sunny Amsterdam!” – Amiram Sananes

The Antibody Society’s Networking Session

The Society hosted a networking session at our booth during the meeting.

Society Sponsors

Society sponsors ImmunoPrecise, Aldevron, Twist Bioscience, and Geneious Biologics were present at the meeting.

We look forward to seeing you at AE&TE in 2020!

All Society members receive discounts on registration for AE&TE, Antibody Engineering & Therapeutics (US), as well as registrations for many antibody-related meetings.

 

 

 

Join Us for Antibody Engineering & Therapeutics Digital Week!

by

Antibody Engineering & Therapeutics Digital Week is a global 4-day series of live educational webcasts and downloadable resources providing the latest insights for accelerating next generation antibodies to commercial success.

The clinical pipeline of antibody therapeutics will be discussed in The Antibody Society’s “Antibodies to Watch” and More: Early- and Late-stage Clinical Development Trends presentation, scheduled for 11am EDT / 4pm BST / 5pm CEST Wednesday June 26, 2019.

The “Antibodies to watch” talks and papers focus on antibody therapeutics in late-stage clinical studies, as well as those is regulatory review and recently approved in the US and European Union. These topics will be discussed, along with trends observed in the burgeoning early-stage pipeline. Popular formats and mechanisms of action, as well as popular and obscure targets, for antibody therapeutics that recently entered the clinical pipeline will be included.

Click here to register for Digital Week.

New antibody-drug conjugate approved in the US

by

On June 10, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Polivy (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (BR), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polivy is composed of a humanized anti-CD79b IgG1 antibody conjugated to the antimitotic agent monomethyl auristatin E (MMAE). The antibody’s target is highly expressed on B cells of patients with lymphoma. The biologics license application for Polivy was granted FDA’s Breakthrough Therapy and priority review designations. The drug also has European Medicines Agency (EMA)’s PRIME designation, and US and EU Orphan Drug designations for DLBCL. EMA is reviewing a marketing authorization application for Polivy.

The drug’s efficacy was evaluated in a study of 80 patients with relapsed or refractory DLBCL who were randomized to receive Polivy with BR or BR alone. Efficacy was based on complete response rate and duration of response (DOR), defined as the time the disease stays in remission. At the end of treatment, the complete response rate was 40% with Polivy plus BR compared to 18% with BR alone. Of the 25 patients who achieved a partial or complete response to Polivy plus BR, 16 (64%) had a DOR of at least six months and 12 (48%) had a DOR of at least 12 months.

Like this post but not a member? Please join!

The Antibody Society maintains a comprehensive table of approved mAb therapeutics and those in regulatory review in the EU or US. Located in the ‘Web Resources’ section of our website, the list is updated regularly and can be downloaded in Excel format. Information about other antibody therapeutics that may enter regulatory review in 2019 can be found in ‘Antibodies to watch in 2019’.

 

Election of new Executive Sub-committee members

by

Members of the 2019/2020 Executive Sub-committee were elected at the AIRR C IV meeting in Genoa in May. Nina Luning Prak (Univ of Pennsylvania) was approved as the Chair of the AIRR Community, Lindsay Cowell (UT Southwestern, USA) was elected the Chair Elect, and Felix Breden (Simon Fraser U, Canada) became the Past Chair. Christian Busse (DKFZ, Germany), Victor Greiff (Univ of Oslo, Norway) also joined the SC.

Short bios of all members of the Executive Sub-committee are presented here: https://www.antibodysociety.org/the-airr-community/airr-subcomittees/executive-sub-committee/.